Thermo Fisher Scientific Inc. $TMO Stock: HF Advisory Group LLC Decreases Stake

HF Advisory Group LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 54.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,129 shares of the medical research company’s stock after selling 1,337 shares during the period. HF Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $762,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Tsfg LLC grew its position in shares of Thermo Fisher Scientific by 20.4% during the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 19 shares during the period. Renasant Bank lifted its stake in Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after purchasing an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. grew its holdings in Thermo Fisher Scientific by 5.4% during the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock valued at $212,000 after purchasing an additional 22 shares during the period. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Finally, Chesapeake Wealth Management raised its stake in shares of Thermo Fisher Scientific by 0.6% in the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company’s stock valued at $1,868,000 after buying an additional 22 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.0%

Thermo Fisher Scientific stock opened at $658.23 on Friday. The stock has a market cap of $243.38 billion, a P/E ratio of 35.41, a PEG ratio of 2.73 and a beta of 0.87. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $694.33. The firm’s fifty day moving average price is $627.39 and its 200-day moving average price is $541.36. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TMO has been the subject of several research reports. Barclays increased their price target on Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research note on Wednesday. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “outperform” rating for the company. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Finally, HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $634.86.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.